|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Osteoarthritis - Drug Development Lags Behind Rising Osteoarthritis Population
Datamonitor, Dec 2009, Pages: 205
Datamonitor expect osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.
Scope
- Snapshot of the osteoarthritis market based on a survey of 180 rheumatologists/primary care physicians, with views from key opinion leader interviews
- Analysis of osteoarthritis epidemiology, with future projections of prevalence and patient numbers to 2020
- Overview of treatment options at the class and molecule level, as well as treatment outcome analysis
- Assessment of treatment satisfaction, unmet needs and physicians' awareness of key pipeline therapies
Highlights of this title
The estimated diagnosis rate of 55% reflects a lack of treatment-seeking by mild sufferers of the disease, who often resort to self-medication. This equates to nearly 37 million undiagnosed patients in 2009 and with a predicted rise in osteoarthritis numbers this is a market with growth potential.
Pain-relieving drugs, particularly, oral non-steroidal anti-inflammatory drugs (NSAIDs) are the foundation of pharmacological therapy in osteoarthritis. Physicians continue to be concerned over NSAID toxicity, with three-quarters of severe patients who are receiving NSAIDs currently co-prescribed a gastroprotectant.
Physicians are generally unsatisfied with current osteoarthritis pharmacological treatments. A clear need for alternative drugs exists to treat this prevalent condition. 41% of physicians ranked disease modifying osteoarthritis drugs (DMOADs) as the highest unmet need, but the majority of physicians estimate that DMOADs are 8 years from the market.
Key reasons to purchase this title
- Understand current therapy trends for the major drug classes used in osteoarthritis split by disease severity and assess unmet needs in the disease
- Validate new product forecasting based on diagnosis rates and treatment by patient segmentation and drug class
- Use the interactive Excel model of treatment trees and patient numbers to estimate the osteoarthritis population in each of the seven major markets
Customers who bought this item also bought
Alzheimer Disease - New Drugs, Markets and Companies
Pain Therapeutics - Drugs, Markets and Companies
Treatment Algorithms: Psoriasis - Prescribing trends mirror guidelines
Psoriasis - Biologics are Yet to Make Topical Treatments Obsolete
Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
Juvenile Idiopathic Arthritis (JIA): KOL Insights on Treatment Practices and Unmet Needs
The Future of Autoimmune Diseases Therapeutics – Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deal Analysis
|
|
|
|
